Guidelines for the Compilation of a Product Dossier for Submission in the Assessment Procedure for New and Multi-Source (Generic) Products Used in the Treatment of Malaria
(11 pages)
Table of Contents
View the documentSection 1. Details of the product
View the documentSection 2. Regulatory situation in other countries
Open this folder and view contentsSection 3. Active pharmaceutical ingredient (s) (API)
Close this folderSection 4. Finished product
View the documentSection 4.1 Formulation
View the documentSection 4.2. Sites of manufacture
View the documentSection 4.3 Manufacturing procedure
View the documentSection 4.4 Specifications for excipients
View the documentSection 4.5 Specifications for the finished product
View the documentSection 4.6 Container/closure system(s) and other packaging
View the documentSection 4.7 Stability testing
View the documentSection 4.8 Container labelling
View the documentSection 4.9 Product information
View the documentSection 4.10 Patient information and package inserts
View the documentSection 4.11 Justification for any differences to the product in the country or countries issuing the submitted WHO-type certificate(s)6
Open this folder and view contentsSection 5. Efficacy and safety
 

Section 4.8 Container labelling

Labelling should include at least the following:

(a) The name of the product;

(b) A list of the active ingredients (using INNs if applicable) showing the amount of each present in a dosage unit, and a statement of the net contents of the container, e.g. number of dosage units, weight or volume;

(c) The batch number assigned by the manufacturer;

(d) The expiry date in an uncoded form;

(e) Any special storage conditions or handling precautions that may be necessary;

(f) Directions for use, and any warnings or precautions that may be necessary;

(g) The name and address of the manufacturer, company or person responsible for placing the product on the market;

(h) The names of any excipients known to be a safety concern for some patients, e.g. gluten, metabisulfite, parabens, ethanol, or tartrazine.


The labelled storage conditions should be achievable in practice in the distribution network.

For containers of less than or equal to 10 ml capacity that are marketed in an outer pack such as a carton, and the outer pack bears all the required information, the immediate container need only contain items (b), (c), (d), (g) - or a logo that unambiguously identifies the company - and the name of the dosage form or the route of administration

to previous section to next section
 

Last updated: May 3, 2013